Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kedrion Fibrin Glue (also referred to as Kedrion Fibrin Sealant) is a plasma-derived biologic hemostatic agent developed by Kedrion S.p.A. It consists of two primary active ingredients: human fibrinogen and human thrombin. When applied topically to a surgical site, these components replicate the final step of the physiological coagulation cascade, where thrombin converts fibrinogen into an insoluble fibrin mesh. This process forms a stable, biodegradable clot that achieves hemostasis and provides tissue sealing. The drug has been evaluated in a multicenter Phase III clinical trial in Italy as an adjuvant hemostatic agent for pediatric patients undergoing abdominal or orthopedic surgery to manage surgical bleeding.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kedrion Fibrin Glue.